XBI — State Street SPDR S&P Biotech ETF
Healthcare Ranked #62 of 458 tracked ETFs · Issued by State Street Investment Management
XBI Price Performance — Growth of $10,000
Value of a $10,000 investment in XBI over time, compared with SPY. Both lines are rebased to $10,000 on the first shared date. Based on total returns — prices are adjusted for dividends and splits, so this assumes distributions were reinvested. Hover or tap the chart for exact values.
XBI Drawdown
The "underwater" chart: XBI's decline from its highest prior value at each point in time. It shows how deep past losses ran and how long the fund took to recover to break-even.
What If You'd Invested in XBI?
See what a lump sum in XBI would have grown to, with the option to add a regular monthly contribution on top. Figures use total returns — dividends are assumed reinvested.
Past performance doesn't predict future results. Assumes contributions on the first trading day of each month, no trading costs or taxes, and reinvested distributions. History is limited to the range published in the site's daily return data.
Overview
The State Street SPDR S&P Biotech ETF is a healthcare-focused fund managed by State Street Investment Management with $11.4 billion in assets under management. It holds a B grade and ranks 1 of 11 within its category, placing it 62nd among 458 tracked ETFs overall. The 0.35% expense ratio sits slightly below the category median of 0.36%, while its 0.35% dividend yield trails the sector median of 0.90%. Top holdings comprise 18.0% of assets, with the largest single position attributed to State Street Global Advisors at 5.9%.
The fund has delivered a 1-year return of +69.55%, significantly outperforming the category median of +24.26%. Short-term momentum shows a divergence, with a 1-month gain of +0.85% contrasting against recent weekly declines of -2.46%. The price of $159.38 sits at 86.4% of its 52-week range, indicating a position near the upper end of recent trading levels. The ETFValuer grade of B has remained unchanged over the last 35 tracked days, based on 3.0 years of available price history.
With a beta of 1.12, the fund exhibits higher sensitivity to market movements compared to the broader index. Annualized volatility of 27.90% is classified as High, accompanied by a maximum drawdown of -32.99%. Despite these fluctuations, the Sharpe ratio of 2.31 suggests strong risk-adjusted returns relative to the volatility experienced. Liquidity is supported by an average daily volume of 8,874,079 shares, facilitating trading activity.
AI-generated summary based on the data on this page.
XBI Top Holdings
| # | Holding | % of Net Assets | Value |
|---|---|---|---|
| 1 | State Street Global Advisors | 5.87% | $631M |
| 2 | Apogee Therapeutics Inc | 1.49% | $160M |
| 3 | Moderna Inc | 1.41% | $152M |
| 4 | Twist Bioscience Corp | 1.41% | $151M |
| 5 | Oruka Therapeutics Inc | 1.38% | $148M |
| 6 | Kymera Therapeutics Inc | 1.36% | $146M |
| 7 | Viking Therapeutics Inc | 1.30% | $140M |
| 8 | Praxis Precision Medicines Inc | 1.29% | $139M |
| 9 | Erasca Inc | 1.27% | $136M |
| 10 | Revolution Medicines Inc | 1.20% | $129M |
Holdings as of 2026-06-30 per the fund's most recent SEC N-PORT-P filing. Top 10 holdings make up 18.0% of net assets — a rough gauge of concentration risk (the higher this figure, the more the fund's return depends on a handful of names). To see how XBI's holdings overlap with other ETFs you own or are considering, check the Stock Overlap tool.
Which Funds Overlap With XBI
Holding two funds that own the same companies adds cost and complexity without adding much diversification. These tracked ETFs share the most names with XBI's top 10 — SPDW overlaps most, holding 1 of the same companies as XBI's top 10 (5.9% of XBI's assets).
| ETF | Name | Shared Companies | XBI Weight | Examples |
|---|---|---|---|---|
| SPDW | State Street SPDR Portfolio Developed World ex-US ETF | 1 | 5.9% | State Street Global Advisors |
| SPEM | State Street SPDR Portfolio Emerging Markets ETF | 1 | 5.9% | State Street Global Advisors |
| SDY | State Street SPDR S&P Dividend ETF | 1 | 5.9% | State Street Global Advisors |
| KRE | State Street SPDR S&P Regional Banking ETF | 1 | 5.9% | State Street Global Advisors |
| JNK | State Street SPDR Bloomberg High Yield Bond ETF | 1 | 5.9% | State Street Global Advisors |
Compares the top 10 reported holdings of each fund, so it's a floor on true overlap — two S&P 500 trackers overlap ~100% even when only 10 names are listed. Use the Stock Overlap tool to search by individual company.
Market Backdrop
10-Year Treasury Yield: 4.80% (as of 2026-09-08) — The yield on 10-year US Treasury bonds — the standard "risk-free rate" benchmark used to contextualize this fund’s Sharpe ratio and returns.
CBOE Volatility Index (VIX): 15.72 (as of 2026-09-08) — A real-time gauge of expected S&P 500 volatility over the next 30 days — useful context for this fund’s own volatility label.
Federal Funds Rate: 3.63% (as of 2026-08-01) — The Federal Reserve’s target policy rate, which anchors short-term borrowing costs across the economy.
What XBI's Fees Cost You
XBI charges an expense ratio of 0.35% a year, deducted automatically from the fund's value. Small percentages compound into real money — adjust the figures below to see the impact on your own numbers.
Assumes a constant gross return and no additional contributions — a simplification, but it isolates exactly what the expense ratio costs. Try the full fee calculator to model contributions and compare any two funds.
XBI Dividend Income Estimator
XBI currently yields 0.35%. Enter an amount to see the income that implies, or set a monthly income target to see the investment it would take.
Based on the fund's current trailing yield, which varies with price and distributions — treat it as an estimate, not a guarantee. Yields are not adjusted for tax.
XBI Liquidity, Domicile & Tax Treatment
Liquidity: Quoted bid/ask spread is — and average daily volume is 8.9M/day. Tighter spreads and higher volume mean lower round-trip trading costs; this is a live-market snapshot and can widen during volatile sessions. AUM of $11.4B provides ample scale, supporting tight spreads and issuer commitment to keep the fund open.
Domicile & tax treatment: XBI is a US-domiciled, SEC-registered ('40 Act) exchange-traded fund. Dividends and capital gains distributions are reported to US investors on Form 1099-DIV, and the fund is not subject to the PFIC reporting or UCITS-specific rules that apply to Irish- or Luxembourg-domiciled funds. Non-US investors should note that US-domiciled ETFs are generally subject to 30% US withholding tax on dividends (unless reduced by treaty) and to US estate tax exposure on the position — Irish-domiciled UCITS ETFs tracking the same index often avoid both, which is why non-US residents frequently prefer the UCITS equivalent where one exists. This is general information, not tax advice — consult a tax professional for your situation.
XBI Performance History
| Period | Return |
|---|---|
| 1-Day | -1.57% |
| 1-Week | -2.46% |
| 1-Month | +0.85% |
| 3-Month | +21.43% |
| 6-Month | +25.20% |
| YTD | +31.28% |
| 1-Year | +69.55% |
| 3-Year | +105.07% |
How XBI Compares to Other Healthcare ETFs
| Rank | Grade | Ticker | Name | 1-Year | Exp. Ratio | AUM |
|---|---|---|---|---|---|---|
| #62 | B |
XBI | State Street SPDR S&P Biotech ETF | +69.55% | 0.35% | $11.4B |
| #74 | B |
VHT | Vanguard Health Care Index Fund ETF Shares | +24.15% | 0.09% | $22.0B |
| #89 | B |
XLV | State Street Health Care Select Sector SPDR ETF | +22.95% | 0.08% | $43.9B |
| #104 | B |
FHLC | Fidelity MSCI Health Care Index ETF | +24.26% | 0.084% | $3.48B |
| #107 | B |
IBB | iShares Biotechnology ETF | +44.87% | 0.44% | $10.5B |
| #150 | B |
XPH | State Street SPDR S&P Pharmaceuticals ETF | +46.56% | 0.35% | $587M |
| #193 | C |
PPH | VanEck Pharmaceutical ETF | +26.39% | 0.36% | $1.03B |
| #197 | C |
IYH | iShares U.S. Healthcare ETF | +22.57% | 0.37% | $3.86B |
| #241 | C |
ARKG | ARK Genomic Revolution ETF | +81.75% | 0.75% | $2.02B |
| #382 | C |
IHF | iShares U.S. Healthcare Providers ETF | +20.41% | 0.37% | $1.23B |
| #446 | F |
IHI | iShares U.S. Medical Devices ETF | -17.32% | 0.37% | $3.47B |